Related Experiment Video

Updated: Dec 3, 2025

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
09:32

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

15.2K

Targeting TIM-3 in solid tumors: innovations in the preclinical and translational realm and therapeutic potential

Reem Saleh1, Salman M Toor1, Eyad Elkord2

  • 1Cancer Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF) , Doha, Qatar.

Expert Opinion on Therapeutic Targets
|October 26, 2020
PubMed
Abstract

Insights

Targeting T cell immunoglobulin and mucin-domain containing protein-3 (TIM-3) shows promise for improving cancer immunotherapy response. Further research is needed to fully understand TIM-3 inhibition

Area of Science:

  • Immunology
  • Oncology
  • Cancer Research

Background:

  • Immune checkpoint inhibitors (ICIs) offer therapeutic benefits but have limited efficacy in many cancer patients.
  • T cell immunoglobulin and mucin-domain containing protein-3 (TIM-3) is a co-inhibitory receptor implicated in immune response attenuation.
  • TIM-3 and its ligands are frequently overexpressed in solid tumors, correlating with poor prognosis.

Purpose of the Study:

  • To review the role of TIM-3 and its ligands in anti-tumor immunity and cancer progression.
  • To examine preclinical models and translational data on the therapeutic potential of targeting TIM-3 signaling.

Main Methods:

  • Comprehensive review of preclinical studies and translational data.
  • Analysis of research published in PubMed up to October 2020.

Main Results:

  • TIM-3 signaling plays a significant role in regulating anti-tumor immune responses.
  • Preclinical data suggest that targeting TIM-3 can enhance anti-tumor immunity.

Conclusions:

  • Targeting TIM-3 represents a promising therapeutic strategy for cancer treatment.
  • Further mechanistic studies are required to elucidate the precise anti-tumor effects of TIM-3 inhibition.
  • Clinical trials are necessary to establish the safety and efficacy of TIM-3 inhibitors in cancer patients.
Keywords:
CancerTIM-3prognostic biomarkersolid tumorstherapeutic target

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.7K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.2K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.1K